8-K: Verrica Pharmaceuticals Reports $3.2 Million in YCANTH Revenue for First Quarter 2024

Verrica Pharmaceuticals announced its first quarter 2024 financial results, highlighted by $3.2 million in revenue from YCANTH and progress in its clinical programs.

Summary

• Verrica Pharmaceuticals reported $3.2 million in product revenue from YCANTH in the first quarter of 2024.
• The company also recognized $0.6 million in collaboration revenue related to its agreement with Torii Pharmaceutical.
• Selling, general, and administrative expenses increased significantly to $16.3 million, primarily due to commercial activities for YCANTH.
• Research and development expenses rose to $4.9 million, driven by increased clinical costs for VP-315.
• The company's net loss for the quarter was $20.3 million, or $0.44 per share, compared to a net loss of $6.6 million, or $0.15 per share, in the same period of 2023.
• Verrica had $48.9 million in cash and cash equivalents as of March 31, 2024, which they believe will fund operations into the first quarter of 2025.
• The company expects to announce preliminary Phase 2 results for VP-315 in the treatment of basal cell carcinoma in the second quarter of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the revenue from YCANTH and regulatory milestones, the significant increase in expenses and net loss are concerning. The company's cash runway is also a potential risk.

Positives

• YCANTH revenue of $3.2 million indicates initial commercial success.
• The permanent J-Code for YCANTH is expected to streamline billing and reimbursement, potentially increasing sales.
• The FDA's NCE status for YCANTH provides a minimum of five years of regulatory exclusivity.
• The company has expanded its distribution network by partnering with Walgreens.
• The Phase 2 trial of VP-315 has completed dosing, with results expected in the second quarter of 2024.

Negatives

• The company experienced a significant net loss of $20.3 million for the quarter.
• Selling, general, and administrative expenses increased substantially to $16.3 million.
• Research and development expenses also increased to $4.9 million.
• The company's cash and cash equivalents decreased from $69.5 million at the end of 2023 to $48.9 million as of March 31, 2024.
• There was an obsolete inventory write-off of $0.3 million.

Risks

• The company is experiencing significant operating losses.
• The company is reliant on the commercial success of YCANTH.
• The company is dependent on the successful development and regulatory approval of its pipeline candidates.
• The company's future financial performance is subject to risks and uncertainties inherent in the drug development and commercialization process.
• The company's ability to fund operations is dependent on its cash reserves and future revenue.

Future Outlook

Verrica expects to announce Phase 2 results for VP-315 in the second quarter of 2024 and believes its current cash will fund operations into the first quarter of 2025.

Management Comments

• The first quarter of 2024 marked a period of significant accomplishments across our business, as we continued to expand utilization of YCANTH, received a permanent J-Code from CMS, and secured new chemical entity status from the FDA for YCANTH, said Ted White, Verricas President and Chief Executive Officer.
• I am also pleased to report that we have seen a meaningful uptick in prescription growth and onboarding of buy and bill accounts following the listing of the permanent J-Code for YCANTH, which went into effect on April 1.

Industry Context

Verrica is operating in the dermatology therapeutics market, focusing on treatments for skin diseases. The company's focus on molluscum contagiosum and basal cell carcinoma addresses significant unmet needs in the market. The receipt of a permanent J-Code and NCE status for YCANTH are important milestones for the company's commercialization efforts.

Comparison to Industry Standards

• Verrica's revenue of $3.2 million from YCANTH is a positive start, but it is still early in the commercialization phase. Companies like Castle Biosciences (CSTL) and DermTech (DMTK) in the dermatology space have reported higher revenues, but they also have more established product portfolios.
• The increase in SG&A expenses is typical for a company launching a new product, but the magnitude of the increase is significant. Companies like Incyte (INCY) and Regeneron (REGN) have much larger SG&A budgets, but they also have significantly higher revenues.
• Verrica's R&D expenses are relatively low compared to larger pharmaceutical companies, but this is expected for a company of its size and stage of development. Companies like Arcutis Biotherapeutics (ARQT) and Marinus Pharmaceuticals (MRNS) have higher R&D expenses, reflecting their focus on multiple clinical programs.
• The net loss of $20.3 million is substantial, but not uncommon for a biotech company in the early stages of commercialization. Many companies in the sector, such as Amylyx Pharmaceuticals (AMLX) and Biohaven (BHVN), have reported significant losses as they invest in R&D and commercialization.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss and increased expenses.
• Employees may be impacted by the company's financial performance and future prospects.
• Customers (healthcare providers and patients) may benefit from the availability of YCANTH and potential future treatments.
• Suppliers may be impacted by the company's financial performance and purchasing decisions.
• Creditors may be concerned about the company's increasing debt and operating losses.

Next Steps

• Verrica will announce preliminary Phase 2 results for VP-315 in the second quarter of 2024.
• The company will continue to focus on the commercial launch of YCANTH.
• Verrica will continue to develop its pipeline candidates.

Key Dates

Keywords

YCANTH, VP-315, molluscum contagiosum, basal cell carcinoma, dermatology, pharmaceuticals, clinical trials, FDA, J-Code, revenue